Rockwell Medical, Inc. (NASDAQ:RMTI) tinted gains of +3.8% (+0.16 points) to US$4.37. The volume of 0.2 Million shares climbed down over an trading activity of 252.8 Million shares. EPS ratio determined by looking at last 12 month figures is -0.54. Over the same time span, the stock marked US$8.7 as its best level and the lowest price reached was US$3.62. The corporation has a market cap of US$236.5 Million.
Rockwell Medical, Inc. (NASDAQ:RMTI)’s earnings per share has been growing at a 28.1 percent rate over the past 5 year when average revenue increase was noted as 2.8 percent. The return on equity ratio or ROE stands at -76.5 percent while most common profitability ratio return on investment (ROI) was -78.8 percent. The company’s institutional ownership is monitored at 32 percent. The company’s net profit margin has achieved the current level of -48.1 percent and possesses 2.4 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 1 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1. 0 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Kura Oncology, Inc. (NASDAQ:KURA) is worth US$664.14 Million and has recently risen 3.78% to US$20.6. The latest exchange of 0.18 Million shares is below its average trading activity of 286.5 Million shares. The day began at US$19.75 but the price moved to US$19.55 at one point during the trading and finally capitulating to a session high of US$20.75. The stock tapped a 52-week high of US$24.02 while the mean 12-month price target for the shares is US$25.4.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 5.26, and a price to sales ratio of 0. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 70.7%, it carries an earnings per share ratio of -1.6.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 4 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 2 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.33.